AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 49 filers reported holding AKERO THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,808,441 | +8.3% | 273,002 | 0.0% | 0.31% | +13.7% |
Q2 2023 | $12,746,463 | +12.7% | 273,002 | -7.6% | 0.27% | +35.5% |
Q1 2023 | $11,305,907 | -34.6% | 295,502 | -6.3% | 0.20% | -45.2% |
Q4 2022 | $17,289,510 | -25.3% | 315,502 | -53.6% | 0.36% | -40.1% |
Q3 2022 | $23,154,000 | +80.3% | 680,000 | -50.0% | 0.61% | +121.5% |
Q2 2022 | $12,843,000 | -33.4% | 1,359,052 | -0.0% | 0.28% | -31.8% |
Q1 2022 | $19,286,000 | -32.9% | 1,359,152 | 0.0% | 0.40% | -9.2% |
Q4 2021 | $28,746,000 | -16.5% | 1,359,152 | -11.8% | 0.44% | -1.3% |
Q3 2021 | $34,429,000 | -16.2% | 1,540,465 | -7.0% | 0.45% | +6.4% |
Q2 2021 | $41,102,000 | -14.5% | 1,656,673 | 0.0% | 0.42% | -10.9% |
Q1 2021 | $48,060,000 | +12.4% | 1,656,673 | 0.0% | 0.48% | +39.7% |
Q4 2020 | $42,742,000 | -16.2% | 1,656,673 | 0.0% | 0.34% | -11.9% |
Q3 2020 | $51,009,000 | +93.7% | 1,656,673 | +56.8% | 0.39% | +60.2% |
Q2 2020 | $26,332,000 | +39.4% | 1,056,673 | +18.6% | 0.24% | -5.5% |
Q1 2020 | $18,893,000 | -4.5% | 891,201 | 0.0% | 0.26% | +3.7% |
Q4 2019 | $19,780,000 | +16.0% | 891,201 | +18.9% | 0.25% | +5.1% |
Q3 2019 | $17,049,000 | +109.5% | 749,424 | +76.3% | 0.23% | +28.6% |
Q2 2019 | $8,139,000 | – | 425,000 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |